Barrow Robert 4

What Happened Robert Barrow, Chief Executive Officer of Definium Therapeutics (DFTX), was granted 320,000 restricted stock units (RSUs) on February 3, 2026. The RSUs were granted at $0.00 per unit (no cash paid) and thus have no immediate purchase value; the filing reports the acquisition as an award rather than an open-market trade.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-05 (reporting period 2026-02-03).
• Transaction type/code: Award/Grant (A).
• Amount: 320,000 RSUs granted at $0.00; reported acquisition value $0.
• Vesting: RSUs vest in 16 equal quarterly installments beginning June 1, 2026, subject to continuous service on each vesting date.
• Shares owned after transaction: Not specified in this filing.
• Notable footnote: Each RSU is a contingent right to receive one common share upon vesting (see vesting schedule above).
• Timeliness: Filing date equals Feb 5, 2026 for a Feb 3, 2026 grant; no late-filing indication in the provided data.

Context This is a compensation-related award, not a purchase or sale. RSU grants are common for executives and generally indicate long-term incentive compensation that vests over time; they do not represent immediately tradable shares until vested and delivered. Such awards are routine corporate governance/compensation actions and should be interpreted accordingly by retail investors.